Theoretical study on the interactions between ibrutinib and gold nanoparticles for being used as drug delivery in the chronic lymphocytic leukemia

被引:5
|
作者
Sanchez-Coronilla, Antonio [1 ]
Martin, Elisa, I [2 ]
Jose Fernandez-de-Cordova, Francisco [3 ]
Prado-Gotor, Rafael [4 ]
Hidalgo, Jose [1 ]
机构
[1] Univ Seville, Fac Farm, Dept Quim Fis, E-41012 Seville, Spain
[2] Univ Seville, Fac Quim, Dept Ingn Quim, E-41012 Seville, Spain
[3] CSIC Univ Sevilla, Inst Invest Quim IIQ, Ave Amer Vespucio 49, E-41092 Seville, Spain
[4] Univ Seville, Fac Quim, Dept Quim Fis, E-41012 Seville, Spain
关键词
ibrutinib; Leukemia; Density functional theory; Gold nanoparticle; Electron localization function; Density of states; INITIO MOLECULAR-DYNAMICS; TOTAL-ENERGY CALCULATIONS; ELECTRON LOCALIZATION; INHIBITORS;
D O I
10.1016/j.molliq.2020.113878
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
A theoretical study of the interaction of ibrutinib with both cysteine!methyl-cysteine and gold surface is presented. The interest of ibrutinib is that binds through its acrylamide group with the S atom from Cys481 residue of Bruton-tyrosine-ldnase (BTK) protein and inhibits the maturation of B-lymphocytes. In a first part, the interaction of ibrutinib through its acrylamide group with cysteine/methyl-cysteine is studied in the range of 298 to 315 K to analyse the effect of increasing the temperature in the binding of the drug with the amine-acid. The interaction is favoured at physiologic temperature but its stability decreases at higher temperatures. Thus, in patients with fever the drug may present a lower effectivity and certain amount of free drug in the blood may appear increasing the risk of toxicity for them. In the second part, the interaction of ibrutinib with a gold surface was studied to explore the possibility of using gold nanoparticles as ibrutinib deliverer. The most stable interaction corresponds to the structure with the nitrogen atoms from pyrimidine moiety and from NH2 directly focused over gold atoms keeping acrylamide group of ibrutinib free for joining to BTK. Therefore, according to the theoretical results gold nanoparticles may be used as ibrutinib deliverer. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页数:7
相关论文
共 46 条
  • [31] Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Burger, Jan
    Barr, Paul
    Robak, Tadeusz
    Owen, Carolyn
    Tedeschi, Alessandra
    Sarma, Anita
    Patten, Piers E. M.
    Grosicki, Sebastian
    McCarthy, Helen
    Offner, Fritz
    Szafer-Glusman, Edith
    Zhou, Cathy
    Szoke, Anita
    Neumayr, Lynne
    Dean, James P.
    Ghia, Paolo
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S342 - S343
  • [32] Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
    S E M Herman
    X Sun
    E M McAuley
    M M Hsieh
    S Pittaluga
    M Raffeld
    D Liu
    K Keyvanfar
    C M Chapman
    J Chen
    J J Buggy
    G Aue
    J F Tisdale
    P Pérez-Galán
    A Wiestner
    Leukemia, 2013, 27 : 2311 - 2321
  • [33] Comparison of Time to Next Treatment Between Patients With Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib Overall and in a Subgroup With High-Risk Characteristics
    Jacobs, Ryan
    Levy, Moshe Y.
    Yazbeck, Victor
    Lafeuille, Marie-Helene
    Emond, Bruno
    Gogna, Priyanka
    Maegawa, Rodrigo
    Qureshi, Zaina P.
    Ferrajoli, Alessandra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S351 - S351
  • [34] Interactions of gold and silica nanoparticles with plasma membranes get distinguished by the van der Waals forces: Implications for drug delivery, imaging, and theranostics
    Jing, Haoyuan
    Sinha, Shayandev
    Sachar, Harnoor Singh
    Das, Siddhartha
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2019, 177 : 433 - 439
  • [35] Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
    Herman, S. E. M.
    Sun, X.
    McAuley, E. M.
    Hsieh, M. M.
    Pittaluga, S.
    Raffeld, M.
    Liu, D.
    Keyvanfar, K.
    Chapman, C. M.
    Chen, J.
    Buggy, J. J.
    Aue, G.
    Tisdale, J. F.
    Perez-Galan, P.
    Wiestner, A.
    LEUKEMIA, 2013, 27 (12) : 2311 - 2321
  • [36] Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
    Mauro, Francesca Romana
    Paoloni, Francesca
    Molica, Stefano
    Reda, Gianluigi
    Trentin, Livio
    Sportoletti, Paolo
    Marchetti, Monia
    Pietrasanta, Daniela
    Marasca, Roberto
    Gaidano, Gianluca
    Coscia, Marta
    Stelitano, Caterina
    Mannina, Donato
    Di Renzo, Nicola
    Ilariucci, Fiorella
    Liberati, Anna Marina
    Orsucci, Lorella
    Re, Francesca
    Tani, Monica
    Musuraca, Gerardo
    Gottardi, Daniela
    Zinzani, Pier Luigi
    Gozzetti, Alessandro
    Molinari, Annalia
    Gentile, Massimo
    Chiarenza, Annalisa
    Laurenti, Luca
    Varettoni, Marzia
    Ibatici, Adalberto
    Murru, Roberta
    Ruocco, Valeria
    Del Giudice, Ilaria
    De Propris, Maria Stefania
    Della Starza, Irene
    Raponi, Sara
    Nanni, Mauro
    Fazi, Paola
    Neri, Antonino
    Guarini, Anna
    Rigolin, Gian Matteo
    Piciocchi, Alfonso
    Cuneo, Antonio
    Foa, Robin
    CANCERS, 2022, 14 (01)
  • [37] Genomic Alterations and Outcomes With Fixed-Duration Ibrutinib plus Venetoclax: Results From the Phase 3 GLOW Study in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Kater, Arnon
    Hodkinson, Brendan
    Moreno, Carol
    Munir, Talha
    Levin, Mark-David
    Niemann, Carsten
    Qi, Keqin
    Sinet, Pierre
    Baeten, Kurt
    Caces, Donne Bennett
    Srinivasan, Srimathi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S329 - S329
  • [38] Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
    Visentin, Andrea
    Mauro, Francesca Romana
    Catania, Gioachino
    Fresa, Alberto
    Vitale, Candida
    Sanna, Alessandro
    Mattiello, Veronica
    Cibien, Francesca
    Sportoletti, Paolo
    Gentile, Massimo
    Rigolin, Gian Matteo
    Quaglia, Francesca Maria
    Murru, Roberta
    Gozzetti, Alessandro
    Molica, Stefano
    Marchetti, Monia
    Pravato, Stefano
    Angotzi, Francesco
    Cellini, Alessandro
    Scarfo, Lydia
    Reda, Gianluigi
    Coscia, Marta
    Laurenti, Luca
    Ghia, Paolo
    Foa, Robin
    Cuneo, Antonio
    Trentin, Livio
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)
    Burger, Jan
    Barr, Paul
    Owen, Carolyn
    Robak, Tadeusz
    Tedeschi, Alessandra
    Bairey, Osnat
    Hillmen, Peter
    Coutre, Steve
    Devereux, Stephen
    Grosicki, Sebastian
    McCarthy, Helen
    Li, Jianyong
    Offner, Fritz
    Moreno, Carol
    Dai, Sandra
    Szoke, Anita
    Dean, James P.
    Kipps, Thomas J.
    Ghia, Paolo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S316 - S316
  • [40] Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study
    Cuneo, Antonio
    Mato, Anthony R.
    Rigolin, Gian Matteo
    Piciocchi, Alfonso
    Gentile, Massimo
    Laurenti, Luca
    Allan, John N.
    Pagel, John M.
    Brander, Danielle M.
    Hill, Brian T.
    Winter, Allison
    Lamanna, Nicole
    Tam, Constantine S.
    Jacobs, Ryan
    Lansigan, Frederick
    Barr, Paul M.
    Shadman, Mazyar
    Skarbnik, Alan P.
    Pu, Jeffrey J.
    Sehgal, Alison R.
    Schuster, Stephen J.
    Shah, Nirav N.
    Ujjani, Chaitra S.
    Roeker, Lindsey
    Orlandi, Ester Maria
    Billio, Atto
    Trentin, Livio
    Spacek, Martin
    Marchetti, Monia
    Tedeschi, Alessandra
    Ilariucci, Fiorella
    Gaidano, Gianluca
    Doubek, Michael
    Farina, Lucia
    Molica, Stefano
    Di Raimondo, Francesco
    Coscia, Marta
    Mauro, Francesca Romana
    de la Serna, Javier
    Medina Perez, Angeles
    Ferrarini, Isacco
    Cimino, Giuseppe
    Cavallari, Maurizio
    Cucci, Rosalba
    Vignetti, Marco
    Foa, Robin
    Ghia, Paolo
    CANCER MEDICINE, 2020, 9 (22): : 8468 - 8479